....however it’s my speculative guess that this firm will have to go through all the trials first...just like RVX. Back in 2007 the rumor was that RVX would be sold “pre clinical” and the price went up to $29 per share....

Very unlikely IMO that Zenith will need to do a Phase III before something happens.  And they are a long way past "pre clinical".

PS.  TD price is at $2.00 USD.